Catyalyst Pharmaceutical (CPRX) Posts Q1 Loss of 7c/Share
Get Alerts CPRX Hot Sheet
Price: $15.13 +2.72%
EPS Growth %: -46.3%
Financial Fact:
Loss from operations: -3.91M
Today's EPS Names:
RUSHA, SEIC, OSBC, More
EPS Growth %: -46.3%
Financial Fact:
Loss from operations: -3.91M
Today's EPS Names:
RUSHA, SEIC, OSBC, More
Join SI Premium – FREE
Catyalyst Pharmaceutical Partners (NASDAQ: CPRX) reported Q1 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).
2014 Business Achievements To Date:
- Completed enrollment of pivotal phase 3 trial of Firdapse™ in patients with LEMS
- Raised $26.8 million, net of expenses, in a public offering of shares of common stock
- Retained a Chief Commercial Officer
- Developing and beginning the execution of a comprehensive pre-launch plan
- Announced initiation of an expanded access program which will allow LEMS patients early access to Firdapse™
- Initiated commercial scale manufacturing and process validation to U.S. FDA standards of Firdapse™, in order to build launch supplies prior to the anticipated launch of Firdapse™
- Initiated a safety and tolerance clinical trial of amifampridine phosphate in patients with renal (kidney) impairment
- Recently exhibited at the annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.
For earnings history and earnings-related data on Catyalyst Pharmaceutical Partners (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
- Capitol Federal Financial (CFFN) Misses Q2 EPS by 1c
- Bernstein on Tesla: 'Widespread deployment of FSD is 5 - 10 years away'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!